Fleebs-Logo
Details werden geladen...

Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy | The Manila Times

STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), were published today in the New England Journal of Medicine.

Ähnliche Seiten

https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/groundbreaking-achievement-study-of-ensartinib-as-postoperative-adjuvant-therapy-published-in-the-new-england-journal-of-medicine/2381317

Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine | The Manila Times

https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/groundbreaking-achievement-study-of-ensartinib-as-postoperative-adjuvant-therapy-published-in-the-new-england-journal-of-medicine/2381317
https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer/2385465

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer | The Manila Times

https://www.manilatimes.net/2026/07/16/tmt-newswire/globenewswire/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer/2385465